GlassScriptPhysician profile
Brandon A E Ruen
NPI 1316438542
$928.12
in general payments reported to CMS, 2019-2025
16 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $228 · 2023: $14.42 · 2024: $30.50 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $200.18 | 2025 | |
| Boston Scientific Corporation | $157.55 | 2025 | Farapulse |
| Abbvie INC. | $128.15 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $110.00 | 2021 | |
| Novo Nordisk INC | $83.40 | 2022-2024 | Wegovy |
| Amgen INC. | $51.51 | 2022 | |
| Phathom Pharmaceuticals, INC. | $30.90 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $30.42 | 2022-2023 | Boostrix, Shingrix |
| Lilly USA, LLC | $27.97 | 2022-2024 | Zepbound, Jardiance |
| Dexcom, INC. | $21.56 | 2022 | |
| Cvrx, INC. | $21.30 | 2025 | Barostim Neo System |
| Takeda Pharmaceuticals U.S.A., INC. | $15.51 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.13 | 2021 | |
| Radius Health, INC. | $13.74 | 2025 | Tymlos |
| Pfizer INC. | $12.94 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $8.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Ruen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.